-
[2,8-bis(trifluoromethyl)quinolin-4-yl](piperidin-2-yl)methanol
-
ChemBase ID:
242
-
Molecular Formular:
C17H16F6N2O
-
Molecular Mass:
378.3121592
-
Monoisotopic Mass:
378.11668246
-
SMILES and InChIs
SMILES:
FC(F)(F)c1nc2c(c(C(O)C3NCCCC3)c1)cccc2C(F)(F)F
Canonical SMILES:
OC(c1cc(nc2c1cccc2C(F)(F)F)C(F)(F)F)C1CCCCN1
InChI:
InChI=1S/C17H16F6N2O/c18-16(19,20)11-5-3-4-9-10(15(26)12-6-1-2-7-24-12)8-13(17(21,22)23)25-14(9)11/h3-5,8,12,15,24,26H,1-2,6-7H2
InChIKey:
XEEQGYMUWCZPDN-UHFFFAOYSA-N
-
Cite this record
CBID:242 http://www.chembase.cn/molecule-242.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
[2,8-bis(trifluoromethyl)quinolin-4-yl](piperidin-2-yl)methanol
|
|
|
IUPAC Traditional name
|
|
Brand Name
|
|
Synonyms
|
Mefloquine HCL
|
Mefloquinone
|
Mefloquine
|
|
|
CAS Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
Data Source
|
Data ID
|
Price
|
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
ALOGPS 2.1
Acid pKa
|
13.785841
|
H Acceptors
|
3
|
H Donor
|
2
|
LogD (pH = 5.5)
|
0.94418555
|
LogD (pH = 7.4)
|
2.0721047
|
Log P
|
4.1105947
|
Molar Refractivity
|
82.5774 cm3
|
Polarizability
|
31.66879 Å3
|
Polar Surface Area
|
45.15 Å2
|
Rotatable Bonds
|
4
|
Lipinski's Rule of Five
|
true
|
Log P
|
3.1
|
LOG S
|
-4.0
|
Solubility (Water)
|
3.80e-02 g/l
|
PROPERTIES
PROPERTIES
Physical Property
Bioassay(PubChem)
Solubility
|
5000 mg/L (HCl salt)
|
Show
data source
|
|
Hydrophobicity(logP)
|
3.9
|
Show
data source
|
|
DETAILS
DETAILS
DrugBank
DrugBank -
DB00358
|
Item |
Information |
Drug Groups
|
approved |
Description
|
A phospholipid-interacting antimalarial drug (antimalarials). It is very effective against plasmodium falciparum with very few side effects. [PubChem] |
Indication |
For the treatment of mild to moderate acute malaria caused by Mefloquineuine-susceptible strains of Plasmodium falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax. Also for the prophylaxis of Plasmodium falciparum and Plasmodium vivax malaria infections, including prophylaxis of chloroquine-resistant strains of Plasmodium falciparum. |
Pharmacology |
Mefloquine is an antimalarial agent which acts as a blood schizonticide. Mefloquine is active against the erythrocytic stages of Plasmodium species. However, the drug has no effect against the exoerythrocytic (hepatic) stages of the parasite. Mefloquine is effective against malaria parasites resistant to chloroquine. Mefloquine is a chiral molecule. According to some research, the (+) enantiomer is more effective in treating malaria, and the (-) enantiomer specifically binds to adenosine receptors in the central nervous system, which may explain some of its psychotropic effects. |
Toxicity |
Oral, rat: LD50 = 880 mg/kg. Symptoms of overdose include nausea, vomiting, and weight loss. |
Affected Organisms |
|
Biotransformation |
Hepatic. Two metabolites have been identified in humans. The main metabolite, 2,8-bis-trifluoromethyl-4-quinoline carboxylic acid, is inactive against Plasmodium falciparum. The second metabolite, an alcohol, is present in minute quantities. |
Absorption |
Well absorbed from the gastrointestinal tract. The presence of food significantly enhances the rate and extent of absorption. |
Half Life |
2 to 4 weeks |
Protein Binding |
98% |
Elimination |
There is evidence that mefloquine is excreted mainly in the bile and feces. Urinary excretion of unchanged mefloquine and its main metabolite under steady-state condition accounted for about 9% and 4% of the dose, respectively. |
Distribution |
* 20 L/kg [healthy adults] |
Clearance |
* 30 mL/min |
External Links |
|
|
PATENTS
PATENTS
PubChem Patent
Google Patent